Alnylam Pharmace. buy Shooter
Start price
16.10.22
/
50%
€191.98
Target price
16.10.23
-
Performance (%)
11.50%
End price
05.02.23
€214.05
Summary
This prediction ended on 05.02.23 with a price of €214.05. The prediction had a final performance of 11.50%. Shooter has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Shooter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 2.115% | 2.115% | 31.797% |
| iShares Core DAX® | 1.395% | -0.272% | 17.642% |
| iShares Nasdaq 100 | 2.287% | 6.912% | 37.651% |
| iShares Nikkei 225® | 1.617% | 3.038% | 12.910% |
| iShares S&P 500 | 0.659% | 3.687% | 29.434% |